Abstract
Chimeric antigen receptor T cell (CAR-T) therapies have now entered mainstream clinical practice with two approved autologous CAR-T products targeting CD19 and numerous other products in early and late phase clinical trials. This has led to a demand for highly sensitive, specific, and easily reproducible methods to monitor CAR-T cells in patients. Here we describe a flow cytometry based protocol for detection of allogeneic CAR-T cells and for monitoring their phenotype and numbers in blood and bone marrow of patients following CAR-T treatment.
Original language | English |
---|---|
Pages (from-to) | 293-308 |
Number of pages | 16 |
Journal | Methods in molecular biology (Clifton, N.J.) |
Volume | 2097 |
DOIs | |
Publication status | Published - 1 Jan 2020 |
Keywords
- Allogeneic
- Cancer
- CAR-T cells
- Flow cytometry
- Gene knockout
- Immunotherapy